Subscribe
Share
Share
Embed
HHS overrules FDA scientists to approve six peptides; Johns Hopkins finds new vitamin A vision role; Oatly launches Fiber line; Spain's olive sector goes functional.
The Trump administration just handed peptide brands a major regulatory opening — over FDA scientists' objections. Plus, Oatly is coming for gut health shelves with a new Fiber line. Two moves that redraw competitive maps today.
In this episode:
The Health Marketing Daily is a concise briefing for marketers and founders in supplements, functional food and consumer health, hosted by Marco & Klara. New episode every day.
Enjoying the show? A quick rating or review on Apple Podcasts or Spotify helps other marketers find us.
Also from Marco & Klara: The FMCG Marketing Daily · The Digital Commerce Daily
The daily briefing for professionals in health, nutrition, and wellness marketing. Every episode covers an ingredient of the day, the latest science and regulatory updates from EFSA and beyond, and the brand and market moves shaping the nutraceutical industry. Hosted by Klara and Marco — evidence-based, no hype, no bro-science. Built for formulators, brand managers, regulatory affairs teams, and anyone building in the health and nutrition space.
Marco: Four stories on the radar today, and it's a strong mix.
Klara: We're starting with a big regulatory move in the US — the Trump administration has overruled FDA scientists to approve six peptides. Then a striking new discovery about vitamin A and vision from Johns Hopkins.
Marco: After that, Oatly goes functional with a new fibre line. And Spain's olive industry makes a serious play for health positioning.
Klara: Let's get into it.
Marco: The US government has just handed the peptide wellness industry a significant regulatory gift — and not everyone in the room agreed with it.
Marco: Peptides are short chains of amino acids. They're used in everything from anti-ageing skincare to performance recovery supplements. For years, the sector has operated in a legal grey zone in the US, because many peptides hadn't gone through formal drug approval. That ambiguity has been sitting over the market like a cloud.
Marco: Here's what changed. The Department of Health and Human Services — HHS — has granted what's called "enforcement discretion" for six specific peptides. In plain English, that means the FDA won't pursue legal action against brands selling these compounds, even without full drug approval. The catch? FDA career scientists reportedly raised safety objections. Those objections were overruled at the political level by Trump-era HHS leadership.
Klara: That detail matters enormously. When a regulatory decision is made over the heads of the scientists who reviewed the evidence, it creates a fragile foundation. If any safety signals emerge with these peptides down the line — adverse events, interactions, long-term effects — the brands who rushed in early will carry that reputational risk. "We were allowed to" is a very different defence from "we were proven safe."
Marco: I take that seriously, but commercially, this opens a door. Peptide brands in the US will accelerate hard now. European wellness marketers should watch that closely.
Klara: And I'd watch the EFSA angle. The European Food Safety Authority hasn't issued any meaningful framework for peptide supplements. If US momentum builds pressure for European regulators to respond, we could see clarification — or a much harder line — coming from Brussels.
Marco: That's a story to keep tracking. Now let's move to our next story.
Klara: Johns Hopkins researchers have found something unexpected about vitamin A — it plays a role in shaping sharp vision before a baby is even born.
Klara: Most people in this industry associate vitamin A with two things: immune function and night vision. Those are the well-established pathways, and EFSA has authorised health claims covering both. But this new research suggests the ingredient's relationship with visual development runs much deeper than that.
Klara: The Johns Hopkins team identified a previously unknown biological mechanism — a specific process by which vitamin A actively contributes to how sharp, detailed vision develops in the womb. This isn't a refinement of existing knowledge. It's a genuinely new piece of the picture. The science on vitamin A has been settled for decades, which makes findings like this relatively rare.
Klara: From a regulatory standpoint, I want to be careful here. A discovery about a mechanism is not the same as a claimable health benefit. EFSA's authorised claims are built on clinical evidence — not just mechanistic insight. So no prenatal brand should be pivoting their packaging tomorrow. What this does is open a research direction. It gives scientists a new question to investigate with proper clinical methodology.
Marco: I hear the caution, but commercially, this matters right now. Prenatal nutrition is one of the most competitive spaces in European supplements. Vitamin A already appears in every prenatal formula. A compelling new story around in-utero eye development — even at the science communication level — gives brands differentiated content. Think educational campaigns, expert partnerships, ingredient transparency messaging. You don't need an approved claim to communicate what science is exploring.
Klara: That's where I'd push back slightly. Consumer trust in prenatal products is hard-won. Leading with preliminary research in that category carries real risk. Brands need to be precise about what is known versus what is emerging.
Marco: Agreed — the framing has to be honest. Transparency is the asset here, not overreach.
Klara: Worth watching closely as this research develops. Now let's move to our next story.
Marco: Oatly is moving into functional fiber beverages — and it changes the competitive map for gut health brands.
Marco: Oatly built its name on oat milk as a sustainable, plant-based dairy alternative. That positioning carried the brand through enormous growth. But plant-based alone isn't pulling the same weight it did three or four years ago. Consumer interest has matured, competition has intensified, and cost pressures are squeezing margins across the category.
Marco: The company has announced a forthcoming Fiber beverage line as its next major innovation push. This is a deliberate pivot toward functional health positioning — specifically gut health — rather than leading with environmental credentials. Oatly is a brand with serious retail distribution across Europe, stocked in major grocery chains, pharmacies, and foodservice. When a brand at that scale enters the fiber drink space, it doesn't just add a product. It reframes the entire shelf.
Marco: For wellness brands that have owned gut health beverages — often smaller, more premium players — this is a direct challenge from a well-funded competitor with mass-market reach and strong consumer recognition.
Klara: From a science angle, I'd look carefully at how Oatly substantiates this. Fiber and gut health is a category where EFSA has authorised specific claims — but they're tightly tied to particular fiber types and precise intake levels. Beta-glucan from oats, for instance, has solid authorised claims around cholesterol and blood glucose. But "fiber drink" as a broad concept doesn't automatically carry that scientific weight. The formulation details will matter enormously.
Marco: And that's the commercial risk. If the product leans on vague wellness language rather than specific, substantiated claims, it could underwhelm a consumer base that's increasingly ingredient-literate.
Klara: Oatly has the brand equity to make this work — but the science has to hold up.
Marco: Now let's move to our final story.
Klara: Spain's table olive industry has just published research results aimed at building a credible health positioning for one of the Mediterranean's oldest staple foods.
Klara: Table olives have always carried a vague health halo — Mediterranean diet, good fats, tradition. But vague halos don't survive in today's functional food market. Retailers want substantiated claims. Consumers want transparency. And dedicated wellness brands have spent years building exactly that kind of scientific credibility. Traditional food sectors are now realising they need to play the same game.
Klara: Interaceituna — the Spanish table olive industry association — has presented findings from its Health Olive project. The initiative was developed in partnership with research institutions and is specifically designed to document the nutritional and health properties of table olives in a way that can support health-based marketing claims. This isn't one brand running a study. This is an entire commodity sector pooling resources to compete in the functional food space.
Klara: From a regulatory standpoint, the path from research findings to authorised health claims in Europe is long and demanding. Under EC 1924/2006 — the EU regulation governing what health claims can appear on food products — EFSA requires robust clinical evidence linked to specific compounds at specific intake levels. Olives contain polyphenols and healthy fats, both of which have established scientific interest. But "contains polyphenols" is not a claimable benefit without a precise, evidenced mechanism attached to it.
Marco: That said, commercially, this strategy is sharp. Producer organisations across Europe — olive oil, dairy, cereals — are watching wellness brands capture premium shelf space and higher margins. Funding collective research is a rational response. Even without approved claims, science investment signals credibility to buyers and retailers.
Klara: The difference between a science story and a claimable benefit is where most of these initiatives stall. Health Olive will be worth tracking closely as those findings face regulatory scrutiny.
Marco: Today's thread across every story is the same — health claims are no longer just a regulatory checkbox, they're the primary commercial battleground.
Klara: And the brands that win will be the ones whose science can actually survive scrutiny, not just a press release.